Carcinoma anaplásico da tiróide: tendências atuais e perspetivas futuras

  • Miguel F. Valente Faculdade de Medicina da Universidade do Porto
  • João Capela-Costa Hospital de São João

Resumo

O carcinoma anaplásico da tiróide é uma neoplasia muito rara, constituindo cerca de 2% dos tumores da tiróide, mas o mais letal de todos. Apesar dos recentes avanços na abordagem da doença e do recurso a tratamentos multimodais, os resultados continuam a ser desoladores com a sobrevida média a rondar os 5-6 meses após o diagnóstico. A pesquisa de novos métodos que permitam o diagnóstico mais precoce dos doentes bem como de novos alvos terapêuticos que sejam tão eficazes quanto seguros é fundamental para melhorar o prognóstico destes pacientes. A última década trouxe-nos descobertas importantes, sobretudo na compreensão dos mecanismos moleculares da desdiferenciação tumoral, que representam boas hipóteses de aumentar a sensibilidade dos meios de diagnóstico e de encontrar novos fármacos para o controlo da doença. As últimas opções no tratamento molecular são inibidores da cinase, anti-angiogénicos, inibidores do proteossoma e fármacos epigenéticos (inibidores da deacetilase das histonas e agentes hipometilizantes). Os resultados de alguns estudos de fase II parecem promissores. Este trabalho revê as ferramentas de diagnóstico e terapêutica utilizadas atualmente e apresenta algumas das descobertas mais recentes no âmbito do tratamento dos doentes com carcinoma anaplásico da tiróide.

Downloads

Dados de Download não estão ainda disponíveis.

Biografias Autor

Miguel F. Valente, Faculdade de Medicina da Universidade do Porto

Mestre em Medicina, Faculdade de Medicina da Universidade do Porto

João Capela-Costa, Hospital de São João

Mestre em Medicina Molecular, Serviço de Cirurgia Geral do Hospital de São João

Referências

Martins TD, Carrilho F, Leitao P, et al. [Anaplastic thyroid tumor: retrospective analysis of 12 cases]. Acta medica portuguesa. 2004;17(5):349-51. PubMed PMID: 16197840.

Smallridge RC, Ain KB, Asa SL, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid : official journal of the American Thyroid Association. 2012;22(11):1104-39. doi: 10.1089/thy.2012.0302. PubMed PMID:23130564.

Suh HJ, Moon HJ, Kwak JY, Choi JS, Kim E-K. Anaplastic Thyroid Cancer: Ultrasonographic Findings and the Role of Ultrasonography- Guided Fine Needle Aspiration Biopsy. Yonsei Medical Journal. 2013;54(6):1400-6. PubMed PMID: WOS:000326415500014.

Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A. Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid. World journal of surgery. 2001;25(5):617-22. doi: 10.1007/s002680020166. PubMed PMID: 113699 89.

Sugitani I, Miyauchi A, Sugino K, Okamoto T, Yoshida A, Suzuki S. Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients. World journal of surgery. 2012;36(6):1247-54. Epub 2012/02/09. doi: 10.1007/s00268-012-1437z. PubMed PMID: 22311136.

Smallridge RC. Approach to the patient with anaplastic thyroid carcinoma. The Journal of clinical endocrinology and metabolism. 2012;97(8):2566-72. Epub 2012/08/08. doi: 10.1210/jc.2012-1314. PubMed PMID: 22869844; PubMed Central PMCID: PMCPmc3410281.

Haymart MR, Banerjee M, Yin H, Worden F, Griggs JJ. Marginal treatment benefit in anaplastic thyroid cancer. Cancer. 2013;119(17):3133-9. PubMed PMID:WOS:000323255600006.

Rajeev P, Ezzat T, Slade M, Sadler GP, Mihai R. Tracheal Stenting has Minimal Impact on Survival in Anaplastic Thyroid Carcinoma. World journal of surgery. 2013;37(11):2589-93. PubMed PMID: WOS:000327222200016.

Nagaiah G, Hossain A, Mooney CJ, Parmentier J, Remick SC. Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. Journal of oncology. 2011;2011:542358. doi: 10.1155/2011/542358. PubMed PMID: 21772843; PubMed Central PMCID: PMC3136148.

Lowe NM, Loughran S, Slevin NJ, Yap BK. Anaplastic Thyroid Cancer: The Addition of Systemic Chemotherapy to Radiotherapy Led to an Observed Improvement in Survival-A Single Centre Experience and the Review of the Literature. Scientific World Journal. 2014. PubMed PMID: WOS:000332252600001.

Lang BH, Lo CY. Surgical options in undifferentiated thyroid carcinoma. World journal of surgery. 2007;31(5):969-77. doi: 10.1007/s00268-007-0776-7. PubMed PMID: 17483987.

Segerhammar I, Larsson C, Nilsson IL, et al. Anaplastic carcinoma of the thyroid gland: treatment and outcome over 13 years at one institution. Journal of surgical oncology. 2012;106(8):981-6. Epub 2012/06/08. doi: 10.1002/jso.23177. PubMed PMID: 22674491.

Orita Y, Sugitani I, Amemiya T, Fujimoto Y. Prospective application of our novel prognostic index in the treatment of anaplastic thyroid carcinoma. Surgery. 2011;150(6):1212-9. Epub 2011/12/06. doi: 10.1016/j.surg.2011.09.005. PubMed PMID: 22136842.

Isham CR, Bossou AR, Negron V, et al. Pazopanib Enhances Paclitaxel-Induced Mitotic Catastrophe in Anaplastic Thyroid Cancer. Science Translational Medicine. 2013;5(166). PubMed PMID: WOS:000313047400004.

Catalano MG, Poli R, Pugliese M, Fortunati N, Boccuzzi G. Emerging molecular therapies of advanced thyroid cancer. Molecular aspects of medicine. 2010;31(2):215-26. doi: 10.1016/j.mam.2010.02.006. PubMed PMID: 20176050.

Antonelli A, Fallahi P, Ulisse S, et al. New targeted therapies for anaplastic thyroid cancer. Anti-cancer agents in medicinal chemistry. 2012;12(1):87-93. Epub 2011/11/03. PubMed PMID: 2204399 2.

Savvides P, Nagaiah G, Lavertu P, et al. Phase II Trial of Sorafenib in Patients with Advanced Anaplastic Carcinoma of the Thyroid. Thyroid : official journal of the American Thyroid Association. 2013;23(5):600-4. PubMed PMID: WOS:000318220700010.

Bible KC, Suman VJ, Menefee ME, et al. A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. The Journal of clinical endocrinology and metabolism. 2012;97(9):3179-84. Epub 2012/07/10. doi: 10.1210/jc.2012-1520. PubMed PMID: 22774206; PubMed Central PMCID: PMCPmc3431569.

Hollebecque A, Massard C, Soria Jc. Vascular disrupting agents: a delicate balance between efficacy and side effects. Current opinion in oncology. 2012;24(3):305-15. Epub 2012/03/14. doi: 10.1097/CCO.0b013e32835249de. PubMed PMID: 22410458.

Sosa JA, Balkissoon J, Lu SP, et al. Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer. Surgery. 2012;152(6):1078-87. Epub 2012/11/20. doi: 10.1016/j.surg.2012.08.036. PubMed PMID: 23158178.

Sosa JA, Elisei R, Jarzab B, et al. Randomized Safety and Efficacy Study of Fosbretabulin with Paclitaxel/Carboplatin Against Anaplastic Thyroid Carcinoma. Thyroid : official journal of the American Thyroid Association. 2014;24(2):232-40. PubMed PMID: WOS:000331245300007.

Wunderlich A, Fischer M, Schlosshauer T, et al. Evaluation of Aurora kinase inhibition as a new therapeutic strategy in anaplastic and poorly differentiated follicular thyroid cancer. Cancer science. 2011;102(4):762-8. Epub 2011/01/11. doi: 10.1111/j.1349-7006.2011.01853.x. PubMed PMID: 21214672.

Libertini S, Abagnale A, Passaro C, et al. AZD1152 negatively affects the growth of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic virus dl922-947. Endocrine-related cancer. 2011;18(1):129-41. Epub 2010/11/13. doi: 10.1677/erc-10-0234. PubMed PMID: 21071467.

Altmann A, Markert A, Askoxylakis V, et al. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2012;53(11):1764-71. Epub 2012/10/12. doi: 10.2967/jnumed.111.101295. PubMed PMID: 23055533.

Catalano MG, Pugliese M, Gargantini E, et al. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo. International journal of cancer Journal international du cancer. 2012;130(3):694-704. Epub 2011/03/15. doi: 10.1002/ijc.26057. PubMed PMID: 21400508.

Catalano MG, Fortunati N, Pugliese M, et al. Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid cancer cells. The Journal of clinical endocrinology and metabolism. 2012;97(7):E1150-9. Epub 2012/05/09. doi: 10.1210/jc.2011-2970. PubMed PMID: 22563106.

Pugliese M, Fortunati N, Germano A, et al. Histone deacetylase inhibition affects sodium iodide symporter expression and induces 131I cytotoxicity in anaplastic thyroid cancer cells. Thyroid : official journal of the American Thyroid Association. 2013;23(7):838-46. Epub 2013/03/28. doi:10.1089/thy.2012.0359. PubMed PMID: 23531031.

Guerra A, Di Crescenzo V, Garzi A, et al. Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review. BMC surgery. 2013;13 Suppl 2:S44-S. PubMed PMID: MEDLINE:24267151.

Soares P, Lima J, Preto A, et al. Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas. Current genomics. 2011;12(8):609-17. doi: 10.2174/138920211798120853. PubMed PMID: 22654560; PubMed Central PMCID: PMC3271313.

Kebebew E, Greenspan FS, Clark OH, Woeber KA, Mcmillan A. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer. 2005;103(7):1330-5. doi: 10.1002/cncr.20936. PubMed PMID: 15739211.

Akaishi J, Sugino K, Kitagawa W, et al. Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma. Thyroid : official journal of the American Thyroid Association. 2011;21(11):1183-9. Epub 2011/09/23. doi: 10.1089/thy.2010.0332. PubMed PMID: 21936674.
Publicado
2017-10-10
Como Citar
VALENTE, Miguel F.; CAPELA-COSTA, João. Carcinoma anaplásico da tiróide: tendências atuais e perspetivas futuras. Revista Portuguesa de Cirurgia, [S.l.], n. 41, p. 29 - 39, out. 2017. ISSN 2183-1165. Disponível em: <https://revista.spcir.com/index.php/spcir/article/view/672>. Acesso em: 13 nov. 2019.
Secção
Artigos de Revisão